TL;DR: The Centers for Medicare & Medicaid Services modified NCD 322, the national coverage determination governing ESA use in cancer patients, effective February 11, 2026. Here's what billing teams need to do.
CMS ESA cancer coverage policy under NCD 322 Medicare has strict hemoglobin thresholds, dose escalation rules, and hard stop criteria that directly affect whether your claims pay or deny. This policy covers epoetin alfa and darbepoetin alfa — the two ESAs most commonly billed in oncology settings. No specific HCPCS billing codes are listed in the updated policy document itself, but the clinical criteria govern every ESA claim you submit to Medicare for cancer patients.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions |
| Policy Code | NCD 322 |
| Change Type | Modified |
| Effective Date | 2026-02-11 |
| Impact Level | High |
| Specialties Affected | Medical Oncology, Hematology/Oncology, Hospital Outpatient, Infusion Centers, ESRD/Dialysis Facilities |
| Key Action | Audit all active ESA orders against hemoglobin thresholds and dose escalation rules before billing claims dated on or after February 11, 2026 |
CMS ESA Cancer Coverage Criteria and Medical Necessity Requirements 2026
The CMS ESA cancer coverage policy under NCD 322 ties reimbursement to a precise sequence of hemoglobin checks and dose decisions. Get any step wrong and you're looking at a claim denial — or worse, a post-payment audit.
Who qualifies at initiation
CMS covers ESA treatment for anemia secondary to myelosuppressive anticancer chemotherapy in patients with solid tumors, multiple myeloma, lymphoma, and lymphocytic leukemia. Medical necessity at initiation requires a hemoglobin level below 10 g/dL — or a hematocrit below 30% — immediately before starting therapy.
That threshold is a hard line. A hemoglobin of 10.1 g/dL does not qualify. Document the pre-treatment lab value in your records and make sure it maps directly to the claim date.
Starting dose rules
The policy sets specific starting dose ceilings. For epoetin, the maximum starting dose is 150 U/kg three times weekly. For darbepoetin alfa, it's 2.25 mcg/kg once weekly. Equivalent doses over other FDA-approved time periods are allowed.
Billing above the starting dose ceiling at initiation — without the dose escalation criteria being met — puts your claim outside covered parameters. This is a documentation problem as much as a billing problem.
The four-week decision point
At four weeks, CMS requires a specific response assessment. To continue ESA therapy at the starting dose, two conditions must both be true: the hemoglobin remains below 10 g/dL (hematocrit below 30%), and the hemoglobin has risen by at least 1 g/dL (hematocrit up by at least 3%) from pretreatment baseline.
If hemoglobin rises less than 1 g/dL after four weeks but the patient still meets the hemoglobin threshold, you get one shot at a dose increase — 25% above the FDA label starting dose, once. That's the only escalation CMS allows under this coverage policy.
The eight-week hard stop
If hemoglobin rises less than 1 g/dL from pretreatment baseline by eight weeks, continued ESA treatment is not reasonable and necessary under Medicare's billing guidelines. Full stop. Claims for ESA beyond that point will not be covered.
This is one of those criteria that billing teams often miss because the clinical team keeps ordering. Make sure your charge capture process has a flag at the eight-week mark. If the oncologist continues the drug beyond week eight without documented response, you need to issue an Advance Beneficiary Notice (ABN) before administering.
Rapid response and dose reduction
The policy also governs what happens when patients respond too well. If hemoglobin rises more than 1 g/dL over any two-week window, ESA treatment is not covered unless the hemoglobin remains below or falls back to less than 10 g/dL. When you resume or continue after a rapid rise, you must reduce the dose by 25% from the previously administered dose.
Document dose reductions explicitly. A claim showing the prior dose without a reduction note — when the two-week rise criterion was triggered — is a denial waiting to happen.
Duration of coverage
ESA treatment duration for each chemotherapy course includes up to eight weeks after the final dose of myelosuppressive chemotherapy in that regimen. That's a meaningful window for ESA billing in oncology, but it has a defined end date tied to each regimen. Track chemotherapy end dates and apply the eight-week tail to your ESA billing calendar.
The policy does not explicitly call out prior authorization requirements at the national level. However, some Medicare Administrative Contractors apply local coverage determination rules on top of NCD 322. Check with your MAC before assuming the national criteria alone govern your claims.
CMS ESA Cancer Exclusions and Non-Covered Indications
The non-covered list in NCD 322 is specific and worth memorizing. These are not gray areas — CMS calls each one not reasonable and necessary.
Anemia from non-treatment causes in cancer patients
If a cancer patient's anemia comes from folate deficiency, B-12 deficiency, iron deficiency, hemolysis, bleeding, or bone marrow fibrosis, ESA treatment is not covered. The anemia must be secondary to myelosuppressive chemotherapy, not a nutritional or mechanical cause.
This is a common claim denial pattern. Document the specific cause of anemia clearly. If the patient has iron deficiency anemia alongside chemotherapy, ESA isn't covered until the iron deficiency is resolved and you can attribute the anemia to the treatment itself.
Specific cancer types
ESAs are not covered for anemia associated with treatment of acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), or erythroid cancers. These diagnoses put you outside covered parameters regardless of hemoglobin levels.
Anemia of cancer (not treatment-related)
If the anemia is from the cancer itself — not from chemotherapy — ESA treatment is not covered. This distinction matters for patients who present with anemia before chemotherapy begins.
Radiotherapy-only patients
Anemia associated only with radiotherapy is excluded. Patients receiving concurrent chemoradiation may qualify if the anemia is attributable to the chemotherapy component, but radiotherapy alone doesn't meet coverage criteria.
Prophylactic use
Using ESAs to prevent chemotherapy-induced anemia before it develops is not covered. Neither is prophylactic use to reduce tumor hypoxia. Both are explicitly excluded.
Hypertension and antibody resistance
Patients with uncontrolled hypertension are excluded from ESA coverage during cancer treatment. So are patients with erythropoietin-type resistance due to neutralizing antibodies. Screen for both before submitting claims.
If you're unsure how these exclusions apply to a patient's specific situation, loop in your compliance officer before the claim goes out.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Anemia from myelosuppressive chemotherapy — solid tumors, multiple myeloma, lymphoma, lymphocytic leukemia | Covered | No codes listed in policy | Hemoglobin < 10 g/dL required; dose and response criteria apply |
| Anemia from folate, B-12, or iron deficiency in cancer patients | Not Covered | — | Treat underlying deficiency first |
| Anemia from hemolysis, bleeding, or bone marrow fibrosis | Not Covered | — | ESA not covered regardless of hemoglobin level |
| Anemia associated with AML or CML treatment | Not Covered | — | Specific cancer types excluded by NCD 322 |
| Anemia associated with erythroid cancers | Not Covered | — | Excluded category |
| Anemia of cancer not related to treatment | Not Covered | — | Must be treatment-induced, not disease-induced |
| Anemia associated with radiotherapy only | Not Covered | — | Excludes RT-only patients; concurrent chemo may qualify |
| Prophylactic ESA to prevent chemotherapy-induced anemia | Not Covered | — | Must be reactive, not preventive |
| Prophylactic ESA to reduce tumor hypoxia | Not Covered | — | Explicitly excluded |
| ESA in patients with erythropoietin resistance from neutralizing antibodies | Not Covered | — | Screen before initiating therapy |
| ESA in cancer treatment patients with uncontrolled hypertension | Not Covered | — | Control hypertension first |
| All other ESA uses not addressed by NCD 322 | MAC Discretion | — | Your local Medicare Administrative Contractor may cover; check your MAC's LCD |
CMS ESA Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit all active ESA orders against the hemoglobin threshold before billing any claim dated on or after February 11, 2026. If the pre-treatment hemoglobin isn't documented below 10 g/dL (or hematocrit below 30%), you don't have a covered claim. |
| 2 | Build the four-week and eight-week response checkpoints into your charge capture workflow. At week four, confirm the hemoglobin rise meets the ≥1 g/dL threshold. At week eight, confirm the patient has responded. Flag any patient who hasn't risen ≥1 g/dL from baseline by week eight — continued ESA billing after that point is not covered under Medicare's billing guidelines. |
| 3 | Set dose escalation rules in your EMR or pharmacy system. The one-time 25% dose increase at week four is the only escalation NCD 322 allows. If your system allows unlimited dose increases, that's a gap. Fix it before claims go out. |
| 4 | Track chemotherapy end dates and apply the eight-week post-treatment tail per regimen. ESA billing coverage ends eight weeks after the final dose of myelosuppressive chemotherapy. Create a field in your billing system for chemotherapy end date so this calculation runs automatically. |
| 5 | Issue ABNs before administering ESA when coverage criteria aren't met. If a patient's hemoglobin is at or above 10 g/dL, if they've hit the eight-week non-response cutoff, or if they fall into an excluded diagnosis category, document the ABN before the injection. This protects your organization from recoupment. |
| 6 | Check your MAC's local coverage determination for ESA uses not addressed by NCD 322. CMS explicitly leaves non-addressed uses to MAC discretion. If you bill for ESA indications outside the covered or non-covered categories in NCD 322, pull your MAC's LCD. Don't assume national silence means MAC coverage. |
| 7 | Review diagnostic coding for every ESA claim. The non-covered list maps to specific diagnoses — AML, CML, erythroid cancers, iron deficiency anemia, uncontrolled hypertension. If those diagnoses appear on the claim alongside ESA, expect a denial. If a secondary diagnosis creates a non-covered condition, document why the primary cause of anemia is treatment-related. |
This is a high-stakes policy for oncology billing. ESA reimbursement per administration isn't trivial, and the criteria for continued use are tighter than many teams realize. If your practice has a high volume of Medicare oncology patients on ESA therapy, have your billing consultant or compliance officer review your current workflows against these updated criteria before the end of Q1 2026.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for ESAs Under NCD 322
The updated NCD 322 policy document does not list specific CPT or HCPCS codes. This is not unusual for a national coverage determination — codes are typically applied through claims processing edits and your MAC's billing guidance rather than in the NCD text itself.
For ESA billing in oncology, your billing team should confirm the applicable HCPCS codes (typically in the J-code range for injectable drugs) with your MAC or refer to the Medicare Physician Fee Schedule and Drug Payment files. Do not use codes that aren't confirmed against your payer's current fee schedule and drug tables.
What to Confirm With Your MAC
- The current HCPCS J-codes for epoetin alfa and darbepoetin alfa
- Whether your MAC has an active local coverage determination that supplements NCD 322
- Any specific diagnosis code edits your MAC applies to ESA claims for cancer patients
Because this policy involves drug administration with precise dosing thresholds, confirm with your MAC — and if you bill in multiple jurisdictions, check each MAC separately. ESA billing guidelines can vary at the local level even when a national coverage determination is in place.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.